Source comparison
BPC-157 for Stress Fracture: Dosing Comparison
Early Intervention (within 48h) 250–500 mcg Twice daily 4–6 weeks 31% faster union, 27% higher load capacity at 8 weeks (Journal of Orthopaedic Research 2019) Highest efficacy window. Targets inflammatory-to-proliferative transition when periosteal cell recrui
This comparison does not assign a generated winner or score.
- Early Intervention (within 48h)
- 250–500 mcg
- Twice daily
- 4–6 weeks
- 31% faster union, 27% higher load capacity at 8 weeks (Journal of Orthopaedic Research 2019)
- Highest efficacy window. Targets inflammatory-to-proliferative transition when periosteal cell recruitment is maximal
- Delayed Start (after 7 days)
- 6–8 weeks
- 12% faster union, no significant difference in ultimate strength (Int J Mol Sci 2020)
- Still beneficial but misses peak mechanistic leverage. Useful for late-diagnosed stress fractures
- Low-Dose Systemic
- 200 mcg
- Once daily
- 8 weeks
- Modest improvement in radiographic healing, no mechanical strength data
- Suboptimal for fractures requiring rapid return to load-bearing. Better suited for soft tissue applications
- Local Injection (near fracture)
- 300–500 mcg
- Comparable to systemic high-dose in animal models, theoretical advantage in localized concentration
- Practical in accessible sites (tibia, metatarsals), impractical for axial skeleton